**Table S1.** Quality assessment of selected reports based on QHES Instrument

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Question** | **Bruyère et al., 2019** | **Scholtissen et al., 2010** | **Segal et al.,**  **2004** | **Black et al., 2009** | **Bruyère et al., 2021** | **Luksameesate et al., 2022** | **Bruyère et al., 2023** |
| Was the study objective in a clear, specific, and measurable manner? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Were the perspective of the analysis (societal, third-party payer, etc.) and reasons for its selection stated? | No | No | No | No | No | Yes | No |
| Were variable estimates used in the analysis from the best available source (i.e., randomized control trial - best, expert opinion - worst)? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| If estimates came from a subgroup analysis, were the groups prespecified at the beginning of the study? | No | No | No | No | No | No | No |
| Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity analysis to cover a range of assumptions? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Was incremental analysis performed between alternatives for resources and costs? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Was the methodology for data abstraction (including the value of health states and other benefits) stated? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Did the analytic horizon allow time for all relevant and important outcomes? Were benefits and costs that went beyond 1 year discounted (3% to 5%) and justification given for the discount rate? | No | No | Yes | Yes | No | No | No |
| Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit costs clearly described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include the major short-term was justification given for the measures/scales used? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Were the health outcomes measures/scales valid and reliable? If previously tested valid and reliable measures were not available, was justification given for the measures/scales used? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Were the economic model (including structure), study methods and analysis, and the components of the numerator and denominator displayed in a clear, transparent manner? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Were the choice of economic model, main assumptions, and limitations of the study stated and justified? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Did the author(s) explicitly discuss direction and magnitude of potential biases? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Were the conclusions/recommendations of the study justified and based on the study results? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Was there a statement disclosing the source of funding for the study? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| **TOTAL** | 88 | 88 | 95 | 95 | 88 | 92 | 88 |
| **QUALITY** | High | High | High | High | High | High | High |